---
title: "SRZN: Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299223813.md"
description: "SZN-8141, a dual Wnt/VEGF modulator, is entering clinical trials for retinal diseases, with the DUET study set to compare it to Vabysmo and focus on efficacy, durability, and retinal reperfusion. Strong IP, robust financing, and a pipeline including SZN-8143 and a candidate for Fuchs' dystrophy support growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-16T18:56:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299223813.md)
  - [en](https://longbridge.com/en/news/299223813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299223813.md)
generator: "portal-rs"
---

# SRZN: Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease

SZN-8141, a dual Wnt/VEGF modulator, is entering clinical trials for retinal diseases, with the DUET study set to compare it to Vabysmo and focus on efficacy, durability, and retinal reperfusion. Strong IP, robust financing, and a pipeline including SZN-8143 and a candidate for Fuchs' dystrophy support growth.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SRZN.US](https://longbridge.com/en/quote/SRZN.US.md)
- [SRZNW.US](https://longbridge.com/en/quote/SRZNW.US.md)

## Related News & Research

- [Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial](https://longbridge.com/en/news/300788834.md)
- [Analyst Maintains Buy on Surrozen, Reiterates $46 Price Target on Novel Wnt Pathway Strategy in Retinal Disease](https://longbridge.com/en/news/296138314.md)
- [LIVE MARKETS-TSMC earnings could cause another round of consensus upgrades](https://longbridge.com/en/news/301145455.md)
- [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md)
- [History Says Infrastructure Booms Create Winners and Losers. Here Are 3 AI Cloud Stocks to Watch.](https://longbridge.com/en/news/301060298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**